Century Therapeutics Inc IPSC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IPSC is a good fit for your portfolio.
News
-
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
-
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
-
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
-
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
-
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
-
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Trading Information
- Previous Close Price
- $3.13
- Day Range
- $2.79–3.22
- 52-Week Range
- $1.28–5.51
- Bid/Ask
- $2.50 / $3.50
- Market Cap
- $191.86 Mil
- Volume/Avg
- 134,089 / 211,750
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 78.55
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 165
- Website
- https://www.centurytx.com
Comparables
Valuation
|
Metric
|
IPSC
|
CLDX
|
ITOS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.97 | 4.82 | 0.66 |
Price/Sales | 78.55 | 260.58 | 30.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
IPSC
CLDX
ITOS
Financial Strength
|
Metric
|
IPSC
|
CLDX
|
ITOS
|
|---|---|---|---|
Quick Ratio | 9.80 | 13.69 | 13.46 |
Current Ratio | 9.92 | 13.87 | 13.76 |
Interest Coverage | −272.09 | — | — |
Quick Ratio
IPSC
CLDX
ITOS
Profitability
|
Metric
|
IPSC
|
CLDX
|
ITOS
|
|---|---|---|---|
Return on Assets (Normalized) | −25.55% | −30.49% | −12.92% |
Return on Equity (Normalized) | −43.95% | −33.19% | −14.67% |
Return on Invested Capital (Normalized) | −40.06% | −32.85% | −18.54% |
Return on Assets
IPSC
CLDX
ITOS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Gqcjphzv | Ndlwx | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xprzzhxd | Vbcnl | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Gcnhnkcp | Cwnksq | $99.5 Bil | |
MRNA
| Moderna Inc | Ymzjkhnt | Byz | $38.8 Bil | |
ARGX
| argenx SE ADR | Kdxllwn | Ywh | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Lbysqlxt | Rzkdx | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wcqwjgw | Zgtzj | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kkxccnwq | Nvhpbvm | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hhkgqrjyzv | Myjkcbr | $12.5 Bil | |
INCY
| Incyte Corp | Wzpttytgv | Ygmxts | $11.6 Bil |